부인과 악성종양의 화학요법 감수성검사를 위한 in Vitro Clonlgenic Assay = In Vitro Clonogenic Assay for Testing of Sensitivity of Chemotherapy of Gynecologic Malignancies

다국어 초록 (Multilingual Abstract)

In vitro clonogenic assay provides a way of testing the effectiveness of chemotherapeutic agents in treatment of cancer as well as a study of tumor biologh Tumor specimens from 19 patients having cervical, ovarian, or endometrial carcinomas were studied with the in vitro clonogenic assay, 9 of which grew in vitro since May, 1985 Various chemotherapeutic agents by the culture surface drug application technique were tested against these tumors on soft agarose The results were as follows: 1 The percentage of tumor specimen which grew in the soft agarose plate was 47 4% Of the 11 cervical cancer studied, 3 grew(27 3% growth rate) Of the 4 ovarian tumors tested in the labortory, 3 grew(75%), 2 of 3 endometrial cancers grew(66 7%) and 1 of 1 adenocarcinoma of unknown primary site grew(100%) 2 Plating efficiencies of cervical cancer were 0 005-0 01%, that of ovarian cancer were 0 008-1 2%, that of endometrial cancer were 0 008-0 1% and that of adenocarcinoma of unknown origin was 0 005-0 05% 3 Of the 3 patients whose cervical cancer specimens grew in culture, the dose-related degree of colony survival at 1/10 peak plasma level was demonstrated in the order of the following: vincristine 32%, cis-platinum 40%, vinblastine 42%, bleomycin 45%, mitomycin-C 50%, methotraxate 55%, cyclophosphamide 64%, 5-fluorouracil 76% and actinomycin-D 78% 4 Of the 3 patients whose ovarian cancer specimens grew in the laboratory, the dose-related degree of colony survival of cis-platinum at peak plasma concentration was 44% 5 Of the 2 patients whose endometrial carcinoma specimens grew in the plate, the dose-related degree of colony survival at 1/10 peak plasma level was as follows: cis-platinum 34%, cyclophosphamide 38%, 5-fluorouracil 42%, mitomycin-C 44%, actinomycin-D 48%, vincristine 48%, methotraxate 60% and bleomycin 64%